MedPath

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

Not Applicable
Completed
Conditions
Anxiety Disorder
Breast Cancer
Depression
Hot Flashes
Registration Number
NCT00022074
Lead Sponsor
Gary Morrow
Brief Summary

RATIONALE: Gabapentin may be effective for the control of hot flashes. It is not yet known if gabapentin is effective in treating hot flashes.

PURPOSE: Randomized clinical trial to study the effectiveness of gabapentin in controlling hot flashes in women who have breast cancer.

Detailed Description

OBJECTIVES:

* Compare the effectiveness and side effects of 2 different doses of gabapentin vs placebo for the control of hot flashes and other vasomotor symptoms in women with breast cancer.

* Compare quality of life, anxiety, and depression in patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center and duration of hot flash symptoms (less than 9 months vs 9 or more months). Patients are randomized to 1 of 3 arms.

* Arm I: Patients receive oral placebo 3 times a day.

* Arm II: Patients receive oral gabapentin at a low dose 3 times a day.

* Arm III: Patients receive oral gabapentin as in arm II for 3 days and then at a high dose 3 times a day.

Treatment on all arms continues for 8 weeks in the absence of unacceptable toxicity. After week 8, patients may receive open-label gabapentin at the discretion of their physicians.

Hot flashes are assessed at baseline and then during weeks 3 and 7 of the study.

Quality of life, anxiety, and depression are assessed at baseline and then at weeks 4 and 8.

Patients are followed at week 12.

PROJECTED ACCRUAL: A total of 408 patients (136 per arm) will be accrued for this study within 18 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

CCOP - Metro-Minnesota

🇺🇸

Saint Louis Park, Minnesota, United States

CCOP - Northern New Jersey

🇺🇸

Hackensack, New Jersey, United States

MBCCOP - Gulf Coast

🇺🇸

Mobile, Alabama, United States

CCOP - Kalamazoo

🇺🇸

Kalamazoo, Michigan, United States

CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.

🇺🇸

Syracuse, New York, United States

CCOP - North Shore University Hospital

🇺🇸

Manhasset, New York, United States

CCOP - Virginia Mason Research Center

🇺🇸

Seattle, Washington, United States

CCOP - Colorado Cancer Research Program, Incorporated

🇺🇸

Denver, Colorado, United States

CCOP - Scottsdale Oncology Program

🇺🇸

Scottsdale, Arizona, United States

CCOP - Greater Phoenix

🇺🇸

Phoenix, Arizona, United States

MBCCOP - Hawaii

🇺🇸

Honolulu, Hawaii, United States

CCOP - Central Illinois

🇺🇸

Decatur, Illinois, United States

CCOP - Wichita

🇺🇸

Wichita, Kansas, United States

CCOP - Dayton

🇺🇸

Dayton, Ohio, United States

CCOP - Southeast Cancer Control Consortium

🇺🇸

Winston-Salem, North Carolina, United States

CCOP - Northwest

🇺🇸

Tacoma, Washington, United States

CCOP - Columbus

🇺🇸

Columbus, Ohio, United States

CCOP - Marshfield Medical Research and Education Foundation

🇺🇸

Marshfield, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath